The potential of nitric oxide releasing therapies as antimicrobial agents

David O. Schairer,1,3 Jason S. Chouake,1,† Joshua D. Nosanchuk2,3 and Adam J. Friedman4,5,*

†These authors contributed equally to this work.

Introduction

Nitric oxide (NO) is a short-lived, diatomic, lipophilic gas that plays an integral role in defending against pathogens. Among its many functions are involvement in immune cell signaling and in the biochemical reactions by which immune cells defend against bacteria, fungi, viruses and parasites. NO signaling directs a broad spectrum of processes, including the differentiation, proliferation, and apoptosis of immune cells. When secreted by activated immune cells, NO diffuses across cellular membranes and exacts nitrosative and oxidative damage on invading pathogens. These observations led to the development of NO delivery systems that can harness the antimicrobial properties of this evanescent gas. The innate microbicidal properties of NO, as well as the antimicrobial activity of the various NO delivery systems, are reviewed.

NO production is a key feature of immune cells. NO is principally synthesized by one of three NO synthase (NOS) enzymes: neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS). The isoforms differ in respect to regulation, amplitude and duration of NO production, as well as cellular and tissue distribution. Both eNOS and nNOS act as constitutively expressed proteins, and their expression is not limited to endothelial cells or neurons. In fact, NO is produced from both nNOS and eNOS during infection and autoimmunity. Cell types that contain eNOS and nNOS generate low fluxes of NO for short periods of time. NO at these low concentrations (< 1 μM) acts as an intracellular signal, activating or inhibiting different proteins. The third isoform, iNOS, which was originally described in activated macrophages, predominantly functions as a component of the innate immune system. Cytokines and microbial products, often acting synergistically, stimulate iNOS expression. iNOS or eNOS are expressed in dendritic cells, natural killer (NK) cells, mast cells, monocytes, macrophages, microglia, Kupffer cells, eosinophils and neutrophils, as well as other cells involved in immune reactions.

Unlike nNOS and eNOS, which are tightly regulated and dependent on calcium entry into the cell, iNOS produces high amounts of NO when induced. When NO is produced at high concentrations (> 1 μM), it is able to perform nitrosation, nitration, and oxidation reactions. iNOS is regulated at multiple levels ranging from its transcription, to its synthesis, stability, activity and degradation. Relative to nNOS or eNOS, iNOS is
less susceptible to feedback inhibition by NO. This allows iNOS to continually produce NO as a means of defense against microbes when activated. The use of exogenous NO for antimicrobial therapy is similar to action of iNOS in that both are designed to produce high amounts of NO for longer periods of time, to fight microbes.

**Biochemistry of NO**

NO is a lipophilic and hydrophilic natural gas, with a small Stokes radius that allows it to cross membranes readily. NO is a radical gas, and is therefore unstable in an oxygen environment. Reactions of NO with oxygen or superoxide spontaneously produce reactive nitrogen and oxygen intermediates that lead to the formation of a variety of antimicrobial species. The formation of these intermediates becomes biologically significant when the concentration of NO is greater than 1 μM. At these concentrations, reactive nitrogen oxide species (RNOS) causes oxidative and nitrosative damage by altering DNA, inhibiting enzyme function, and inducing lipid peroxidation, which account for the majority of NO’s antimicrobial properties.

NO derivative molecules such as peroxynitrite (ONOO−), S-nitrosothiol (RSNO), nitrogen dioxide (NO2), dinitrogen trioxide and dinitrosyl-iron complexes are generated. Other NO-related species may be formed within target microbes if oxygen radicals are also present. Each of these species is distinct and has its own molecular stability and reactivity. Peroxynitrite, which has greater cytotoxic potential than NO or O2− alone is an example of the synergy between ROS and RNOS interactions.

Like NO, peroxynitrite is also capable of passing through cell membranes; however its greater reactivity with lipids and proteins may limit its ability to diffuse into target cells relative to NO. Nitrogen dioxide can be formed from the autoxidation of NO, or by the oxidation of NO2− by myeloperoxidase and H2O2. Potent nitrosating agents can arise from the auto-oxidation of NO− with thiols and nonheme iron. Reactive nitrogen intermediates can also react with proteins through heme groups, iron sulfur clusters, phenol or aromatic amino acid residues or amines.

**Inherent Antimicrobial Properties of NO**

Chemical alteration of DNA by RNOS is one of the main mechanisms of NO mediated antimicrobial action. NO damages DNA by three mechanisms: direct reaction of RNOS with DNA structure, inhibition of DNA repair and increased generation of alkylating agents and hydrogen peroxide, which are genotoxic. NO itself does not chemically alter DNA, but rather damage is caused by RNOS formed from the autoxidation of NO. N-nitrosating intermediates (N2O3 has been proposed) deaminate cytosine, adenine and guanine. Peroxynitrite and NO2− in particular induce DNA strand breaks, abasic sites and other DNA alterations. NO related DNA damage has also been shown in intact bacteria. NO inhibits DNA repair enzymes associated with the repair of alkylating to DNA. DNA alkyl transferases have cysteine residues whose -SH group reacts with NO to form S-NO adducts.

These adducts inhibit the transfer of the alkyl group from guanine to the protein. RNOS are capable of reacting with and modifying proteins at cysteine, methionine, tyrosine, phenylalanine and tryptophan residues. NO-associated lipid damage has been demonstrated with peroxynitrite and nitrogen dioxide. Peroxynitrite has been shown to mediate lipid peroxidation of liposomes. Lipid peroxidation has been shown to contribute to the antimicrobial activities of NO.

The cytotoxic actions of NO are enhanced by the production of acid, glutathione, and reactive oxygen species (ROS) by macrophages. S-nitrosylation (addition of NO− to sulfhydryl groups) of thiols is an important mechanism for NO mediated toxicity against microbes. S-nitrosothiols (RSNO), N2O3 and dinitrosyl-thiol-iron complexes are potent nitrosylators. GSNO can be actively taken up and processed by microbial systems which typically function to import glutathione and other short peptides. Modification of thiols can alter protein function, and the alteration of surface thiols has been implicated in S-nitrosothiol mediated inhibition of Bacillus cereus spores.

NO readily reacts with proteins that contain heme moieties. These include guanylate cyclase, cytochrome P450 and NO. At low concentrations, NO binds reversibly to the Fe(II) moiety in the guanylate cyclase, ultimately resulting in activation of the protein. At high concentrations, RNOS irreversibly binds to heme proteins, resulting in heme removal from the protein. The release of iron from metalloenzymes causes bacterial iron depletion. NO′ has been shown to reduce Fe(III) complexes, allowing for the enhancement of Fe(II) catalyzed formation of hydroxyl radicals.

Gas and NO play a role in host defense. Enteropathogens are capable of surviving for long periods of time in acid alone, but the combination of acid and nitrite is bactericidal. The role of acidified nitrate is also relevant to combating common cutaneous pathogens. Nitric oxide can be generated from sweat nitrates in the acidic environment of the skin surface, and this is thought to protect against potential invasion by pathogens.

Interestingly, while NO can boost the antimicrobial function of the respiratory burst, it can also protect host cells from oxidative injury. NO′ antagonizes oxidant membrane injury by terminating lipid peroxidation reactions. Though NO can protect against hydrogen peroxide mediated cytotoxicity in mammalian cells, it dramatically potentiates the cytotoxicity of hydrogen peroxide in E. coli. Prokaryotes are more sensitive to NO/H2O2 treatment because bacteria depend on iron sulfur clusters to a greater extent than mammalian cells. The subsequent degradation of these proteins by NO or RNOS allows the released Fe to bind DNA. This free iron is then capable of catalyzing the formation of highly reactive free radicals that damage membranes and DNA.

As microbial resistance to antibiotic therapy is a growing threat to our ability to combat infection, it is important to determine if there are any mechanisms that would confer resistance of NO to bacteria. To date the ability of bacteria to develop resistance to exogenous NO treatments has yet to be demonstrated. In a recent study, the potential for Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), Staphylococcus epidermidis, E. coli and Pseudomonas aeruginosa to develop NO resistance was evaluated.
using spontaneous and serial passage mutagenesis assays. No significant increase in MIC for any of the bacterial species was observed. The lack of bacterial resistance is attributed to the multiple mechanisms of NO generated bacterial toxicity. The versatility of NO allows it to quickly penetrate microbial cell membranes, where various nitrosative and oxidative reactions can proceed, as discussed above. In order for microbial resistance to occur, multiple bacterial mutations would have to evolve concurrently. There are properties that can confer some protection from NO to bacteria. Several studies show that bacterial exposure to NO leads to increased expression of bacterial enzymes that have evolved to detoxify this radical. Flavohemoglobin analogs are known to be protective in cells that are exposed to NO, including S. aureus and S. Typhimurium. The induction of lactate dehydrogenase (LDH) by NO observed in methicillin-sensitive (MSSA) and methicillin-resistant S. aureus protects the bacteria from physiologic concentrations of NO. NO induced LDH allows S. aureus to maintain redox homeostasis during nitrosative stress. These mechanisms are specific for allowing microbes to survive host defenses. However, these compensatory mechanisms are not capable of protecting pathogens from the high levels of NO exposure seen with the use of NO donor drugs. These drugs are microbicidal for a wide array of pathogens, including S. aureus. The inherent broad spectrum antimicrobial activity of NO make it a worthy target for development and clinical use.

Nitric Oxide Delivery Platforms

In order to harness the potential benefits of NO as an antimicrobial agent, this evanescent gas needs to be delivered to target cells at precise concentrations for significant periods of time in a convenient and non-toxic manner. Only a handful of NO delivery platforms have been evaluated for their antimicrobial properties. The NO delivery platforms evaluated include: gaseous NO from a tank, NO generation from a probiotic patch, NO released or donated from a pro-drug, and release and generation from nanoparticles.

Gaseous NO. The antimicrobial properties of NO were initially investigated by exposing pathogens to gaseous NO (gNO). Simple application of gNO was effective against bacteria, fungi, mycobacteria, parasites and viruses. In order to deliver gNO to an infected tissue a specialized chamber is required. The chamber allows for controlled delivery of NO and prevents oxygen species from reacting with the NO to produce toxic NO₂. Continuous exposure to 80 ppm gNO in the controlled chamber inhibited growth of P. aeruginosa and S. aureus. When levels are raised to 160 ppm, gNO is bactericidal. Interestingly, intermittent exposure for 30 min every four hours is also effective, but requires twice the concentration of gNO to be bactericidal. At 200 ppm, gaseous NO reduced S. aureus burden in a rabbit wound model but was not cytotoxic to human fibroblast, keratinocyte, endothelial, monocyte and macrophage cells in culture. Although effective, the delivery device is cumbersome as it includes pressure regulators, heaters, humidifiers and multiple tanks of gas. Furthermore, in order to achieve the reported results, three 8 h treatment sessions were required. Gaseous NO is already approved for the treatment of pulmonary hypertension of the newborn where it has proven to be a safe and cost-effective alternative to extracorporeal membrane oxygenation. Clinical experience with gNO shows that it is a viable option for the hospital setting where patients are immobile and there is access to specialized equipment, but it is too costly (at $125 per hour of treatment) and impractical for other settings.

NO probiotic patch. A probiotic patch that releases gNO has also been developed. In this system, immobilized Lactobacilli convert glucose into lactic acid. The lactic acid reacts with nitrite salt to produce gNO that then diffuses through the mesh lining of the patch to reach the target tissue. The production of lactic acid by bacteria limits the rate at which NO is formed and allows for continued production of variable levels of NO for over a 24 h period. Because the rate of NO production is dependent on the activity of the lactobacilli, there is patch to patch variability in peak gNO production. Some patches produce in excess of 400 ppm gNO while others do not surpass 150 ppm. Despite the variability in NO production, in vitro tests have shown the patch to be cidal against E. coli, S. aureus, P. aeruginosa, MRSA, T. mentagrophytes, T. rubrum and have demonstrated some activity against A. baumannii. In vivo results were less favorable—in an S. aureus-infected open wound model the patch reduced bacterial burden, but this impact did not reach statistical significance. The probiotic patch may be a viable alternative to gNO from a tank as it is capable of producing similar concentrations of gNO, but at this time the patch requires additional modifications to achieve consistent release rates.

Acidified nitrite. Acidified nitrite creams also produce NO through the reaction of nitrite with an acid. Unlike the probiotic patch that relies on lactic acid, acidified nitrite creams use ascorbic acid to reduce nitrite to NO. These two part cream preparations are easy to transport and use but must be mixed together.

![Figure 1. Chemical structure of sodium nitrite (A), diazeniumdiolate bound to an amine group (B) and S-Nitrosothiols group (C).](image-url)
immediately before being applied. Another advantage of the cream is it penetrates the skin and produces NO within the follicular ostia. The potency of the cream can be regulated by varying the concentration of nitrite and ascorbic acid. The standard preparation produces a quick burst of NO (12 ppm) that drops rapidly over one hour. Comparatively weak to gNO delivery devices, daily treatment with acidified nitrite cream is still effective against tinea pedis, molluscum contagiosum, mycobacterium ulcers and MRSA abscesses in human trials. The low levels of NO may still be effective because of the cream’s ability to penetrate the skin as well as to stimulate the host immune system. Leishmania in culture is also sensitive to acidified nitrite, but when applied to human subjects, only 28% showed clinical improvement. Although effective against a variety of cutaneous infections, the use of acidified nitrite cream is limited by skin irritation. When applied to normal skin, the resulting erythema and inflammation are equivalent to that of psoriasis. Given the variety of non-irritating antimicrobial treatments available, the irritating effects of acidified nitrite are likely to be a barrier to use of the drug.

**Organic nitrates and sodium nitroprusside.** NO donor drugs are the largest and most well understood of the NO delivery systems. Sodium nitroprusside and organic nitrates (nitroglycerin and isosorbide mononitrate) are not used as antibiotics, but are commonly used as blood pressure lowering medications to treat cardiovascular disease. Sodium nitroprusside spontaneously releases NO, but gives off carbon monoxide as a byproduct. Organic nitrates only release NO in tissues expressing the enzyme mitochondrial aldehyde dehydrogenase 2, but this enzyme is irreversibly inactivated with use and causes tachyphylaxis (also known as nitrite/nitrate tolerance). These drugs have limited antibacterial and biofilm disrupting properties and are unlikely to be used as antibacterial agents given their potent cardiovascular effects.

**Diazeniumdiolate (NONOates).** Diazeniumdiolates, also known as NONOates, consist of a diolate group \(-\text{N}(-\text{O})_{n} = \text{O}\) bound to a nucleophile adduct (Fig. 1B). Frequently, the nitrogen of an amine group is used as the nucleophile. A diolate group can be added to nitrogen by exposing the base compound to gNO in the absence of oxygen. The simplicity of diazeniumdiolate synthesis has allowed for a variety of NONOates to be created. In the same way that NO molecules are added to the base compound, NONOates spontaneously release up to two molecules of NO. The rate of release is dependent on the stability of bond between the nucleophile and the diazeniumdiolate. Side groups joined to the nucleophile can alter the rate of NO release from seconds to hours or even prevent release of NO until the side group is enzymatically cleaved. Not all NONOates are clinically useful because the parent compound may become toxic when the diazeniumdiolate group is converted to a reactive N-nitroso group. For example, O(2)-vinyl 1-(pyrrolidin-1-yl)diazen-1-iium-1,2-diolate (V-PYRRO/NO) is a NONOate that is activated by hepatic cells. The N-nitroso byproduct of V-PYRRO/NO metabolism is the potent hepatocarcinogen N-nitrosopyrrolidine. Clearly, toxic or carcinogenic NONOates should not be used to treat infections when many effective and non-toxic alternatives exist. Two major strategies have been adopted in an effort to mitigate toxicity: using an established drug or a ubiquitous molecule already present in cells as the parent molecule or incorporating the parent compound into a large, insoluble structure.

Although there is a large number of NONOates being investigated for use as vasodilators or as chemotherapeutics, only a few have been evaluated for their antimicrobial activity. Diethylenetriamine, a ubiquitous polyanine found in both eukaryotic and prokaryotic cells, can be used to make the NONOate DETA-NO. DETA-NO is effective against gram negative and gram positive bacteria. Furthermore DETA-NO inhibits candidal growth and acts synergistically withazole antifungals. In an effort to further reduce the potential toxicity of the diazeniumdiolate, a hybrid of ketoconazole diazeniumdiolate was synthesized and shown to be more potent than ketoconazole alone. NONOate coatings, especially those based on established medications, are a promising source of NO releasing antimicrobials and would benefit from further study.

In order to reduce the risk of the toxic metabolites, several groups have created NONOate-coated surfaces to large immobile structures and nanoparticles. Sol-gel based coatings which integrate N-(6-aminohexyl) aminopropyltrimethoxysilane (AHAP) can be loaded with diazeniumdiolates. When the NO molecules are subsequently released, the metabolites remain bound to the sol-gel coating. However, even with the application of a surface coating, the toxic N-nitroso groups are still cytotoxic to adjacent fibroblast cells at antimicrobial concentrations (40%). Atomic force microscopy of E. coli and P. aeruginosa exposed to NONOate coatings showed disorganized adhesion and increased surface roughness similar to the changes caused by amoxicillin. These findings suggest that NONOate coatings are as effective in perturbing cell wall structure as a traditional antibiotic that targets cell wall synthesis. In in vitro studies of silicone and steel polypropylene implants, NONOate coatings decreased bacterial adhesion of S. aureus, E. coli and P. aeruginosa. The results of the two available in vivo studies are mixed. In the first study, NONOate-coated silicone implants decreased the rate of infection by 82%. The second study found an increased number of bacteria surrounding the NONOate coated polypropylene implants, but the coating on the polypropylene implant only released 1/6 as much NO as the coating used in the first study. Clearly, proper NO dosing is critical to the antimicrobial activity of NO delivery systems. A NO releasing wound dressing made from nanofibers has also been developed. The dressing inhibited S. aureus growth in vitro and, in a small human case series, accelerated healing of cutaneous leishmaniasis ulcers. The major limitation of NONOate coatings is the cytotoxicity and the limited number of NO molecules that can be released by the coating in comparison to the lifetime of the device. Nonetheless, the initial release of NO during the first 24 h after implantation is sufficient to decrease the rate of infection, making the currently available coatings clinically valuable.

**S-nitrosothiols.** S-nitrosothiols are molecules that contain NO bound to a thiol (sulfhydryl) group (R-SH; Fig. 1C). NO is released when the bond between the two is cleaved. Although this
process occurs in the physiologic environment, it does not occur spontaneously. Three mechanisms of release have been identified: copper ion-mediated decomposition, direct reaction with ascorbate and homolytic cleavage by 550–600 nm wavelength light.80-82 Additionally, S-nitrosothiols can transfer bound NO to other thiol groups through a process called transnitrosylation.83 Multiple modes of action may give S-nitrosothiols unique properties compared with gNO and other NO donors. A disadvantage of S-nitrosothiols is that target pathogens have clearance mechanisms that rapidly degrade the active form of the drug.84 S-nitrosoglutathione and S-nitroso-N-acetylcysteine are bactericidal against common Gram-negative and Gram-positive pathogens.85,86 GSNO is bactericidal at concentrations safe to human cells—about twice the concentration of GSNO in human serum.87,88 S-nitrosothiols like GSNO, SNAC and S-nitroso-N-acetyl-DL-penicillamine (SNAP) have antimicrobial activity against parasites including Leishmania species,89 T. cruzi,90 P. falciparum91 and A. castellanii92 in vitro. Cystine residues found in proteins can also be S-nitrosylated. This technique has led to S-nitrosylation of albumin which is effective against S. Typhimurium in vitro.93 Human studies of S-nitrosothiols are limited to case reports and one small study of 16 patients with cutaneous leishmaniasis. All patients treated with SNAP had complete healing of their ulcers while those treated with vehicle did not. Multiple cases of recurrence were noted and SNAP treatment is not recommended.94

Zeolites. Zeolites are nanoporous materials composed of a metal-organic framework. Their large surface area and metallic components allow zeolites to bind large amounts of NO relative to their size. Although stable when dry, when exposed to moisture the water molecules force NO from the zeolite.95 The rate of NO release can be adjusted by altering the composition of the metal-organic framework. Although NO releasing zeolites are a recent discovery, they were shown to have antibacterial properties against P. aeruginosa, MRSA, C. difficile,96 E. coli and B. subtilis.97 For the zeolites examined, NO release is rapid (peaking after 10 min) and short lived (complete release after 1 h). Fast releasing zeolites could be used as disinfectants or as a coating for medical devices. Further work may lead to slow releasing zeolites more suitable for treating infections.

Nanoparticle Platforms

Nanoparticle platforms have unique properties conferred upon them by their small size. In regards to NO delivery, the design of the nanoparticle can influence release rates and sites of delivery.7,98-100 Furthermore, certain nanoparticles have intrinsic antimicrobial activity or can deliver multiple drugs simultaneously. Because these platforms are versatile and customizable, they are an optimal system for delivering NO.

Silica-based nanoparticles can be fashioned from the same materials used to make NONOate implant coatings.99,100 One technique developed by Carpenter, Slomberg, Rao and Schoenfisch99 replaces the steel surface of an implant with a silica-based AHAP doped sol-gel. These NONOate covered nanoparticles are effective against P. aeruginosa in vitro. As the size of the particles shrinks, more nanoparticles are able to associate with the surface of the pathogen and the antimicrobial activity rises. Remarkably, the toxicity to human fibroblast in culture did not increase with the smaller-sized particles. In a different study, a NONOate coated silica nanoparticles synthesized without micelles were more effective than a small molecule NONOate in killing P. aeruginosa. The same nanoparticles were bactericidal when applied to P. aeruginosa, E. coli, S. aureus, S. epidermidis and C. albicans biofilms.100 At concentrations sufficient to kill about 99% of the bacteria in a biofilm, the nitric oxide releasing nanoparticles were no more toxic to fibroblasts than the antiSeptics povidoneiodine and chlorhexidine.

In reviewing the various platforms and their shortcomings, a platform that does not rely on NO-donating chemicals or external reducing agents to generate and release NO would be ideal. Recently, a sol-gel based NO releasing nanoparticle (NO-np) was described that can generate NO through the thermal reduction of nitrite and release it in a slow, sustained manner.7 The core of the nanoparticle is composed of a tetramethoxysilane derived silica network augmented with polyethylene glycol (PEG), chitosan and a glass forming disaccharide (Fig. 2). During synthesis, nitrite is encapsulated within the composite matrix of the nanoparticle and then reduced to NO. Production of NO from nitrite is accomplished by a thermal reduction process requiring the long range transport of electrons from the sugar glass throughout the composites extensive hydrogen bonding network.7,101,102 Chitosan is a positively charged natural polymer that contributes to the structure of the nanoparticle but also has antimicrobial properties of its own.103 After the sol-gel is lyophilized it spontaneously breaks into nanoparticles. The final product is shelf stable at room temperature until it is exposed to moisture. The dry nanoparticles are 10 nm in diameter and form aggregates approximately 130 nm across.7 Once exposed to water, the nanoparticles expand and steadily release NO over 24 h. The rate and total NO released can be modified by changing the amount of nitrite or the molecular weight and the concentration of PEG incorporated into the molecule. The nanoparticle platform shows minimal toxicity to human fibroblasts in culture,7 applied topically in various murine models, or when administered intravenously in a hamster model.104 NO-np has clinical potential because it is an inexpensive, simple to synthesize, shelf stable and nontoxic method for the sustained delivery of NO.

In culture, both Gram-positive (MRSA, S. pyogenes and E. faecalis) and Gram-negative (E. coli, K. pneumoniae and P. aeruginosa) bacteria are killed by NO-np doses corresponding to 1.25–5 μM NO.105 Bacteriostatic concentration of NO-np inhibited growth for 12 to 24 h dependent on bacterial species. When NO-np was co-administered with glutathione (GSH), GSNO was generated from the nitrosylation of GSH. This combination treatment even more potently inhibited the growth of MRSA, E. coli, P. aeruginosa and K. pneumonia in culture.106 In murine models, topically applied NO nanoparticles were also effective in decreasing bacterial burden in MRSA-infected wounds.
by 99.9%,\textsuperscript{107} MRSA-infected dermal abscesses by 81%\textsuperscript{108} and \textit{A. baumannii}-infected wounds by approximately 90%.\textsuperscript{109} In a MRSA intramuscular abscess model, topical and intralesional NO-np were superior to vancomycin. While vancomycin decreased wound burden by 94%, topical NO-np and intralesional NO-np reduced bacterial burden by 98% and 99%, respectively.\textsuperscript{110} NO-np is also effective against fungal infections caused by \textit{C. albicans} (Nacherla et. al, in press) and \textit{T. metagrophytes} (unpublished findings). An additional benefit of NO-np is their proven ability to accelerate wound healing through recruitment of macrophages, upregulation of collagen gene expression, and acceleration of neoangiogenesis as compared with wounds treated with an empty nanoparticle.\textsuperscript{111}

While other NO delivery systems are bulky, expensive, toxic or unstable, NO-np is a potent and locally acting antimicrobial that is low cost, shelf stable and easy to apply. The combination of broad spectrum antimicrobial activity and the ability to accelerate healing makes NO-np an ideal candidate for treating contaminated wounds. Future work with NO-np is directed at further characterizing its antimicrobial properties in animal models of infection and eventually in human trials.

\textbf{Conclusion}

NO is an important cellular signaling molecule and potent antimicrobial. Its role in physiologic function as well as its potential as a therapeutic agent won it the title of \textit{Molecule of the Year} in 1992. Over the ensuing 20 years, a plethora of delivery systems have been developed to harness NO for clinical use. Only a few of the available systems have been assessed for their efficacy as an antimicrobial. However, the NO delivery systems assessed thus far exhibit a broad spectrum of antimicrobial activity in vitro and in vivo. The limited work in humans shows that topically delivered NO is clinically useful and no more toxic than currently available antimicrobials. Presently, research into the use of NO as an antimicrobial is focused on characterizing and optimizing delivery systems using in vitro and animal studies. In the future, studies need to investigate the safety, efficacy and feasibility of use in humans.

\textbf{Declaration of Conflict of Interests}

Drs Joshua Nosanchuk and Adam Friedman are on the Advisory Board of Makefield Therapeutics.

\textbf{References}

1. Fang FC. Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 1997; 99:2818-25; PMID:9185502; http://dx.doi.org/10.1172/JCI119473
2. Tripathi P, Tripathi P, Kashyap L, Singh V. The role of nitric oxide in inflammatory reactions. FEMS Immunol Med Microbiol 2007; 51:443-52; PMID:17903207; http://dx.doi.org/10.1111/j.1574-695X.2007.00329.x
3. Andreakis N, D’Aniello S, Albalat R, Patti FP, Garcia-Fernández J, Procaccini G, et al. Evolution of the nitric oxide synthase family in metazoans. Mol Biol Evol 2011; 28:163-79; PMID:20639231; http://dx.doi.org/10.1093/molbev/msq179
4. Joerink M, Savelkoul HFJ, Wiegertjes GF. Evolutionary conservation of alternative activation of macrophages: structural and functional characterization of arginase 1 and 2 in carp (Cyprinus carpio L.). Mol Immunol 2006; 43:1116-28; PMID:16257446; http://dx.doi.org/10.1016/j.molimm.2005.07.022
5. Privett BJ, Broadnax AD, Bauman SJ, Riccio DA, Schoenfisch MH. Examination of bacterial resistance to exogenous nitric oxide. Nitric Oxide 2012; 26: 160-73; PMID:22549019; http://dx.doi.org/10.1016/j.niox.2012.02.002
6. Ghaffari A, Miller CC, McMullin B, Ghahary A. Potential application of gaseous nitric oxide as a topical antimicrobial agent. Nitric Oxide 2006; 14:21-9; PMID:16188471; http://dx.doi.org/10.1016/j.niox.2005.08.003
7. Friedman AJ, Han G, Navati MS, Checco M, Gunther L, Aflort J, et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitric containing hydrogel/glass composites. Nitric Oxide 2008; 19:12-20; PMID:18456780; http://dx.doi.org/10.1016/j.niox.2008.04.008

8. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15:323-50; PMID:9143469; http://dx.doi.org/10.1146/annurev.immunol.15.1.323

9. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2:907-16; PMID:11577346; http://dx.doi.org/10.1038/nn1001-97

10. Durand JL, Mukherjee S, Commodari F, De Souza AP, Zhao D, Machado FS, et al. Role of NO synthase in the development of Trypanosoma cruzi-induced cardiomycopathy in mice. Am J Trop Med Hyg 2009; 80:782-7; PMID:19160724

11. Cui X, Besch V, Khabullina A, Hergen A, Quezado M, Eichacker P, et al. Neuronal nitric oxide synthase deficiency decreases survival in bacterial peritonitis and sepsis. Intensive Care Med 2007; 33:1993-2003; PMID:17667624; http://dx.doi.org/10.1007/s00134-007-0814-9

12. Bogdan C. Regulation of lymphocytes by nitric oxide. Mol Cells 2011; 30:677-93; PMID:20941622; http://dx.doi.org/10.1007/s10059-010-2430-2

13. Wink DA, Mitchell JB. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med 1998; 25:434-56; PMID:9741580; http://dx.doi.org/10.1016/S0891-5849(98)00092-6

14. Thomas DS, Ridnour LA, Beneger JF, Flores-Santana WR, Bergonia HA, Müller C, Pitt BR, Watkins WD, Lancaster JR, Jr. Nitric oxide and intracellular signaling. Free Radic Biol Med 2006; 41:1504-12; PMID:17023267; http://dx.doi.org/10.1016/j.freeradbiomed.2005.01.025

15. Björne H, Weitzberg E, Lundborg J. Intragastric generation of antimicrobial nitric oxides from saliva-physiological and therapeutic considerations. Free Radic Biol Med 2006; 41:1404-12; PMID:17023267; http://dx.doi.org/10.1016/j.freeradbiomed.2006.07.020

16. de Groote MA, Fang FC. NO inhibitions: antimicrobial properties of nitric oxide. Clin Infect Dis 1995; 21(Suppl 2):S162-5; PMID:8845445; http://dx.doi.org/10.1093/clinids/21.Supplement_2.S162

17. Ghaffari A, Neil DH, Ardakani A, Road J, Ghahary A, Miller CC. A direct nitric oxide gas delivery system for bacterial and mammalian cell cultures. Nitric Oxide 2005; 12:129-40; PMID:15797841; http://dx.doi.org/10.1016/j.niox.2004.11.006

18. Miller C, McMillan B, Ghaffari R, Ahrer R, Roscoe D, et al. Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure. Nitric Oxide 2009; 20:16-23; PMID:19235644; http://dx.doi.org/10.1016/j.biomaterials.2008.10.002

19. Ghaffari A, Julié RL, Ghaffari M, Miller C, Ghahary A. Efficacy of gaseous nitric oxide in the treatment of skin and soft tissue infections. Wound Repair Regen 2007; 15:368-77; PMID:17573124; http://dx.doi.org/10.1111/j.1524-725X.2007.00239.x

20. Angus DC, Clermont G, Watson RS, Linde-Zwibbel WT, Clark RH, Roberts MS. Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the United States. Pediatrics 2003; 111:1351-60; PMID:14656609; http://dx.doi.org/10.1542/peds.111.4.1351

21. Jones ML, Ganopoulos JG, Llabé A, Prakash S. A novel nitric oxide producing probiotic patch and its antimicrobial efficacy: preparation and in vitro analysis. Appl Microbiol Biotechnol 2010; 87:509-16; PMID:20307478; http://dx.doi.org/10.1007/s00253-010-2490-x
66. Kröncke K-D, Suschek CV. Adulterated effects of nitric oxide-releasing diazeniumdialate. Annu Rev Pharmacol Toxicol 2006; 46:435-58; PMID:16421512; http://dx.doi.org/10.1146/annurev.pharmaco.46.032805.100857

67. Keefer LK. Progress toward clinical application of the nitric oxide-releasing diazeniumdialate. Annu Rev Pharmacol Toxicol 2006; 46:435-58; PMID:16421512; http://dx.doi.org/10.1146/annurev.pharmaco.46.032805.100857

68. Tabor H, Tabor CW. Biosynthesis and Metabolism of 1,4-diaminobutane, Spermidine, Spermine, and Related Amines. Advances in Enzymology and Related Areas of Molecular Biology: John Wiley & Sons, Inc.; 2006:203-268.

69. Raulli R, McElhaney-Feser G, Hrabie J, Cihlar R. Antimicrobial properties of nitric oxide using diazene-dialates as the nitric oxide donor. Rec Rev Microbiol. 2002; 6:177-83.

70. Dukelow AM, Weetcker S, Karachi TA, Razavi HM, McMorrack DG, Joseph MG, et al. Effects of nebulized diethyldithiocarbamate-NONOate in a mouse model of acute Pseudomonas aeruginosa pneumonia. Chest. 2002; 122:2127-36; PMID:12478587; http://dx.doi.org/10.1378/chest.122.6.2127

71. McElhaney-Feser GE, Raulli RE, Cihlar RL. Synergy of nitric oxide and azoles against Candida species in vitro. Antimicrob Agents Chemother 1998; 42:2342-6; PMID:9736560

72. Konter J, Mollmann U, Lehmann J. NO-donors. Part 17: Synthesis and antimicrobial activity of novel keracoxa-NO-donor hybrid compounds. Bioorg Med Chem 2008; 16:8294-300; PMID:18710813; http://dx.doi.org/10.1016/j.bmc.2008.05.088

73. Nablo BJ, Prichard HL, Butler RD, Kitzman B, Schoenfisch MH. Inhibition of implant-associated infections via nitric oxide release. Biomaterials 2005; 26:9586-98; PMID:15798663; http://dx.doi.org/10.1016/j.biomaterials.2005.02.017

74. Nablo BJ, Rothrock AR, Schoenfisch MH. Nitric oxide-releasing sol-gels as antibacterial coatings for orthopedic implants. Biomaterials 2005; 26:917-24; PMID:15355203; http://dx.doi.org/10.1016/j.biomaterials.2004.03.031

75. Engelman AF, Krom BP, Busscher HJ, van Dam GM, Ploeg RJ, van der Mei HC. Antimicrobial effects of an NO-releasing poly(ethylene vinylacetate) coating on soft-tissue implants in vitro and in a murine model. Acta Biomater 2009; 5:1905-10; PMID:19251498; http://dx.doi.org/10.1016/j.actbio.2009.01.041

76. Shin JH, Merger SK, Schoenfisch MH. Synthesis of nitric oxide-releasing silica nanoparticles. J Am Chem Soc 2007; 129:4612-9; PMID:17735919; http://dx.doi.org/10.1021/ja070543h

77. Chariote GW, Herriott MY, Greer CB, Schoenfisch MH. Reduced bacterial adhesion to fibroinogen-coated substrates via nitric oxide release. Biomaterials 2008; 29:1049-59; PMID:18658757; http://dx.doi.org/10.1016/j.biomaterials.2007.10.005

78. Nablo BJ, Schoenfisch MH. In vitro cytotoxicity of nitric oxide-releasing sol-gel derived materials. Biomaterials 2005; 26:4405-15; PMID:15701369; http://dx.doi.org/10.1016/j.biomaterials.2004.11.015

79. Bhide M. Nitric oxide delivery from polymeric wound dressings. The University Of Akron; 2006.

80. Kröner K-D, Suschek CV. Adulterated effects of nitric oxide-generating donors. J Invest Dermatol 2008; 128:258-60; PMID:18195740; http://dx.doi.org/10.1038/jid.2008.162

81. Hogg N. Biological chemistry and clinical potential of S-nitrosothiols. Free Radic Biol Med 2000; 28:1478-86; PMID:10927172; http://dx.doi.org/10.1016/s0891-5849(00)00248-3

82. Laver JR, Stevani TM, Messenger SL, Lunn AD, Lee ME, Moir JW, et al. Bacterial nitric oxide detoxification prevents host cell S-nitrosothiol formation: a novel mechanism of bacterial pathogenesis. FASEB J 2010; 24:286-95; PMID:19720623; http://dx.doi.org/10.1096/faseb.08-128330

83. Souza-Lima RA, Sr, Cariello AJ, Bispo M, Sr, et al. Bacterial Effect Of Nitric Oxide Donors Against Clinical Isolates From Keratitis. Invest Ophthalmol Vis Sci 2011; 52:5839-41.

84. Marckmann J. Nitric oxide and antimicrobial activity of reactive oxygen intermediates. Immunopharmacology 1997; 37:35-41; PMID:9282542; http://dx.doi.org/10.1016/s0165-1101(97)80016-8

85. Richic JP, Jr., Skowronski I, Abraham P, Leutinger Y. Blood glutathione concentrations in a large-scale human study. Clin Chem 1996; 42:64-70; PMID:8562352

86. Bryan NS, Rassaf T, Maloney RE, Rodriguez CM, Sajio F, Rodriguez JR, et al. Cellular targets and mechanisms of nitrosylation: an insight into their nature and kinetics in vivo. Proc Natl Acad Sci U S A 2004; 101:4018-3; PMID:15041475; http://dx.doi.org/10.1073/pnas.0310670101

87. de Souza GFP, Yokoyama-Yasunaka JKU, Sebrab AB, Mendonca DC, de Oliveira MG, Uliana SRB. Leishmanidal activity of primary S-nitrosothiols against Leishmania major and Leishmania amazonensis: implications for the treatment of cutaneous leishmaniasis. Nitric Oxide 2006; 15:209-16; PMID:16527502; http://dx.doi.org/10.1016/j.niox.2006.01.011

88. Vespa GN, Canha FQ, Silva JS. Nitric oxide is involved in control of Trypanosoma cruzi-induced paraesthesia and directly kills the parasite in vitro. Infect Immun 1994; 62:5177-82; PMID:7523307

89. Rockett KA, Awbourn MM, Cowden WB, Clark IA. Killing of Plasmodium falciparum in vitro by nitric oxide derivatives. Infect Immun 1991; 59:3280-3; PMID:1879941

90. Cariello AJ, de Souza GFP, Fondona AS, Yu MCZ, Holfing-Lima AL, de Oliveira MG. In vitro amoebicidal activity of S-nitrosoglutathione and S-nitroso-N-acetylcysteine against trophozoites of Acanthamoeba castellanii. J Antimicrob Chemother 2006; 65:588-91; PMID:17075322; http://dx.doi.org/10.1093/iancm/ggl203

91. Ishima Y, Sawa T, Kragh-Hansen U, Miyamoto Y, Matsushita S, Akaike T, et al. S-Nitrosylation of the nitric oxide-releasing diazeniumdialate. Free Radic Biol Med 2000; 28:1478-86; PMID:10927172; http://dx.doi.org/10.1016/s0891-5849(00)00248-3

92. Miller MR, Megson IL. Recent developments in nitric oxide donor drugs. Br J Pharmacol 2007; 151:305-21; PMID:17401442; http://dx.doi.org/10.1038/bjp.2007.722

93. Keefer LK. Nitric oxide (NO)- and nitroson (HNO)-generating diazeniumdialates (NONOates): emerging commercial opportunities. Curr Top Med Chem 2009; 9:625-39; PMID:19161164; http://dx.doi.org/10.2174/15680260978459380

94. Kröncke K-D, Suschek CV. Adulterated effects of nitric oxide-generating donors. J Invest Dermatol 2008; 128:258-60; PMID:18195740; http://dx.doi.org/10.1038/jid.2008.162

95. Wheatley PS, Butler AR, Crane MS, Fox S, Xiao B, Rossi AG, et al. NO-releasing zeolites and their antibacterial properties. J Am Chem Soc 2006; 128:502-9; PMID:16420837; http://dx.doi.org/10.1021/ja0570579

96. Fox S, Wilkinson TS, Wheatley PS, Xiao B, Moeris RE, Sutherland A, et al. NO-loaded Zn(2+)-exchanged zeolite materials: a potential bifunctional anti-bacterial strategy. Acta Biomater 2010; 6:1513-21; PMID:19861185; http://dx.doi.org/10.1016/j.actbio.2009.03.038
97. Narin G, Albayrak ÇR, Ülkü S. Antibacterial and bactericidal activity of nitric oxide-releasing natural zeolite. Appl Clay Sci 2010; 50:560-8; http://dx.doi.org/10.1016/j.clay.2010.10.013

98. Jin Y, Lohstreter S, Pierce DT, et al. Silica Nanoparticles with Continuously Tunable Sizes: Synthesis and Size Effects on Cellular Contrast Imaging. Chemistry of Materials. 2008; 20:4411-9; http://dx.doi.org/10.1021/cm8007478

99. Carpenter AW, Slomberg DL, Rao KS, Schoenfisch MH. Influence of scaffold size on bactericidal activity of nitric oxide-releasing silica nanoparticles. ACS Nano 2011; 5:7235-44; PMID:21842899; http://dx.doi.org/10.1021/nn202054f

100. Hertick EM, Shin JH, Paul HS, Schoenfisch MH. Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles. Biomaterials 2009; 30:2782-9; PMID:19233464; http://dx.doi.org/10.1016/j.biomaterials.2009.01.052

101. Ray A, Friedman BA, Friedman JM. Trehalose glass-facilitated thermal reduction of metmyoglobin and methemoglobin. J Am Chem Soc 2002; 124:7270-1; PMID:12071726; http://dx.doi.org/10.1021/ja0203438

102. Navari MS, Friedman JM. Sugar-derived glasses support thermal and photo-initiated electron transfer processes over macroscopic distances. J Biol Chem 2006; 281:36021-8; PMID:17005567; http://dx.doi.org/10.1074/jbc.M608686200

103. Rabea EI, Badawy MET, Stevens CV, Smaghi G, Steurbaut W. Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules 2003; 4:1457-65; PMID:14606868; http://dx.doi.org/10.1021/bm034130m

104. Cabrales P, Han G, Roche C, Nacharaju P, Friedman AJ, Friedman JM. Sustained release nitric oxide from long-lived circulating nanoparticles. Free Radic Biol Med 2010; 49:530-8; PMID:20460149; http://dx.doi.org/10.1016/j.freeradbiomed.2010.04.034

105. Friedman A, Blecher K, Sanchez D, Tuckman-Vernon C, Gualanella P, Friedman JM, et al. Susceptibility of Gram-positive and negative bacteria to novel nitric oxide-releasing nanoparticle technology. Virulence 2011; 2:217-21; PMID:21577055; http://dx.doi.org/10.4161/viru.2.3.16161

106. Friedman AJ, Blecher K, Schairer D, Tuckman-Vernon C, Nacharaju P, Sanchez D, et al. Improved antimicrobial efficacy with nitric oxide releasing nanoparticle generated S-nitrosoglutathione. Nitric Oxide 2011; 25:381-6; PMID:21946032; http://dx.doi.org/10.1016/j.niox.2011.09.001

107. Martinez LR, Han G, Chacko M, Mihu MR, Jacobson M, Gualanella P, et al. Antimicrobial and healing efficacy of sustained release nitric oxide nanoparticles against Staphylococcus aureus skin infection. J Invest Dermatol 2009; 129:2463-9; PMID:19587479; http://dx.doi.org/10.1038/sj.jid.2009.95

108. Han G, Martinez LR, Mihu MR, Friedman AJ, Friedman JM, Nosanchuk JD. Nitric oxide releasing nanoparticles are therapeutic for Staphylococcus aureus abscesses in a murine model of infection. PLoS One 2009; 4:e7804; PMID:19915659; http://dx.doi.org/10.1371/journal.pone.0007804

109. Mihu MR, Sandikovsky U, Han G, Friedman JM, Nosanchuk JD, Martinez LR. The use of nitric oxide releasing nanoparticles as a treatment against Acinetobacter baumannii in wound infections. Virulence 2010; 1:46-7; PMID:21178416; http://dx.doi.org/10.4161/viru.1.2.18038

110. Schairer D, Martinez LR, Blecher K, Chouke J, Nacharaju P, Gualanella P, et al. Nitric oxide nanoparticles: Pre-clinical utility as a therapeutic for intramuscular abscesses. Virulence 2012; 3:62-7; PMID:22286699; http://dx.doi.org/10.4161/viru.3.1.18816

111. Han G, Nguyen LN, Macherla C, Chi Y, Friedman JM, Nosanchuk JD, et al. Nitric oxide-releasing nanoparticles accelerate wound healing by promoting fibroblast migration and collagen deposition. Am J Pathol 2012; 180:1465-73; PMID:22306734; http://dx.doi.org/10.1016/j.ajpath.2011.12.013